Does TAFASITAMAB Cause Disease progression? 470 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 470 reports of Disease progression have been filed in association with TAFASITAMAB (MONJUVI). This represents 33.8% of all adverse event reports for TAFASITAMAB.
470
Reports of Disease progression with TAFASITAMAB
33.8%
of all TAFASITAMAB reports
239
Deaths
54
Hospitalizations
How Dangerous Is Disease progression From TAFASITAMAB?
Of the 470 reports, 239 (50.9%) resulted in death, 54 (11.5%) required hospitalization, and 13 (2.8%) were considered life-threatening.
Is Disease progression Listed in the Official Label?
Yes, Disease progression is listed as a known adverse reaction in the official FDA drug label for TAFASITAMAB.
What Other Side Effects Does TAFASITAMAB Cause?
Diffuse large b-cell lymphoma (346)
Off label use (203)
Death (146)
Neutropenia (99)
Covid-19 (96)
General physical health deterioration (75)
Pneumonia (66)
Febrile neutropenia (64)
Drug ineffective (62)
Thrombocytopenia (60)
What Other Drugs Cause Disease progression?
RITUXIMAB (7,282)
CYCLOPHOSPHAMIDE (7,100)
DOXORUBICIN (6,165)
VINCRISTINE (5,252)
PREDNISONE (5,096)
BEVACIZUMAB (4,653)
DEXAMETHASONE (4,545)
CARBOPLATIN (4,538)
CAPECITABINE (3,808)
ETOPOSIDE (3,776)
Which TAFASITAMAB Alternatives Have Lower Disease progression Risk?
TAFASITAMAB vs TAFASITAMAB-CXIX
TAFASITAMAB vs TAFINLAR
TAFASITAMAB vs TAFLUPROST
TAFASITAMAB vs TAGRAXOFUSP-ERZS
TAFASITAMAB vs TAHOR